Massimo Breccia and Sapienza University - Free people check

(1 - 8 from 9

)

Loop | Massimo Breccia

loop.frontiersin.org

Dr. Massimo Breccia is a medical assistant at Sapienza University of Rome, Azienda Policlinico Umberto I.His scientific interests and publications as author or co-author (more than 300 papers in peer reviewed journals) are mainly focused on biological and clinical aspects of acute and chronic myeloid leukemias and myelodysplastic syndromes.

Presentación de PowerPoint - Vall d'Hebron Institute of Oncology

www.vhio.net

Dr. Massimo Breccia. Hematology - Sapienza University of Rome MONITORING MILESTONES IN PATIENTS WITH CML. Dra. Adoración Blanco ...

Adherence and future discontinuation of tyrosine kinase inhibitors in...

www.sciencedirect.com

Massimo Breccia. Search for articles by this author Affiliations. Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy;

Disappearance of fibrosis in secondary myelofibrosis after...

link.springer.com

Massimo Breccia (1) Author Affiliations. 1. Department of Cellular Biotechnologies and Hematology, Sapienza University, Via Benevento 6Rome, Italy ...

All web results to the name "Massimo Breccia"

‪massimo breccia‬ - ‪Google Scholar‬

scholar.google.co.uk

‪Sapienza University‬ - ‪‪Cited by ‬‬ - ‪Hematology‬

Frontiers | BCR-ABL1 Doubling-Times and Halving-Times May ...

www.frontiersin.org

Aug 13, · Massimo Breccia, Sapienza University of Rome, Italy. Reviewed by: Valentin Garcia-Gutierrez, Ramón y Cajal University Hospital, Spain Rehan Khan, Mayo Clinic Arizona, United States Alejandro Majlis, Las Condes Clinic, Chile.

Systematic review of dasatinib in chronic myeloid leukemia | OTT

www.dovepress.com

Systematic review of dasatinib in chronic myeloid leukemia Massimo Breccia, Adriano Salaroli, Matteo Molica, Giuliana Alimena Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy Abstract: Dasatinib is a dual tyrosine kinase inhibitor active against ABL and Src family kinases, and is approved for the treatment of chronic myeloid leukemia (CML) patients in ...

The Real-World Role for Second-Line Ponatinib in CML Is ...

www.cancertherapyadvisor.com

Aug 07, · “Ponatinib was put on hold by FDA for the increased risk of cardiovascular events,” Massimo Breccia, MD, of Sapienza University of Rome in Italy, told Cancer Therapy Advisor.

Related search requests for Massimo Breccia

Daniela Diverio
Roberto Latagliata
Bruno Martino

Sergio Amadori

People
Forename "Massimo" (9911)
Name "Breccia" (50)

sorted by relevance / date

Advanced Search

Search name: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Massimo Breccia and Sapienza University Free People Check